Zimmer Biomet resolved the FDA's June 3, 2015, Warning Letter.
Here are three takeaways:
1. The Warning Letter regarded Zimmer Biomet's Zhejiang, China manufacturing facility.
2. During a January 2015 onsite inspection, the FDA found manufacturing practice issues.
3. Zimmer Biomet President and CEO noted the company "will continue to take the necessary actions to demonstrate our commitment to quality excellence, patient safety and regulatory compliance."